Yongxu Mu1, Xiaoyan Hu2, Junfeng He2, Haiyan Liu2, Lei Zhang2, Heming Liu1, Zhiming Hao3. 1. Department of Endocrinology, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University Xi'an 710049, China ; Department of Intervention, The First Affiliated Hospital of Baotou Medical College Baotou 014010, China. 2. Department of Intervention, The First Affiliated Hospital of Baotou Medical College Baotou 014010, China. 3. Department of Endocrinology, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University Xi'an 710049, China.
Abstract
AIMS: This study is to investigate the expression levels of vascular endothelial growth factor (VEGF) and cancer antigen 125 (CA125) in serum of adenomyosis patients before and after interventional therapy. The role of serum levels of VEGF and CA125 for the prognosis of adenomyosis is further studied. METHODS: A total of 80 adenomyosis patients treated with interventional therapy and 40 healthy individuals were enrolled in this study. Enzyme-linked immunosorbent assay was performed to detect the expression levels of VEGF and CA125. Receiver operating characteristic analysis was used to determine the treatment effect on adenomyosis. Kaplan-Meier analysis was used to analysis the progression-free survival curve for prognosis of adenomyosis. RESULTS: The expression levels of VEGF and CA125 in serum of patients with adenomyosis was increased when compared with those of healthy individuals before interventional therapy (P < 0.05). Levels of hemoglobin in adenomyosis patients after surgery was increased compared with those before surgery (P < 0.05). The blood volume of menstruation, pain intensity, and volume of uterus in adenomyosis patients after surgery was significantly decreased when compared with those before surgery (P < 0.01). The survival rate of adenomyosis patients with high VEGF and CA125 levels was decreased. Serum levels of VEGF and CA125 had a high sensitivity and specificity for the prognosis of adenomyosis. CONCLUSIONS: The serum expression levels of VEGF and CA125 are related to the development of adenomyosis. VEGF and CA125 serum levels can be used for predicting the prognosis of adenomyosis.
AIMS: This study is to investigate the expression levels of vascular endothelial growth factor (VEGF) and cancer antigen 125 (CA125) in serum of adenomyosispatients before and after interventional therapy. The role of serum levels of VEGF and CA125 for the prognosis of adenomyosis is further studied. METHODS: A total of 80 adenomyosispatients treated with interventional therapy and 40 healthy individuals were enrolled in this study. Enzyme-linked immunosorbent assay was performed to detect the expression levels of VEGF and CA125. Receiver operating characteristic analysis was used to determine the treatment effect on adenomyosis. Kaplan-Meier analysis was used to analysis the progression-free survival curve for prognosis of adenomyosis. RESULTS: The expression levels of VEGF and CA125 in serum of patients with adenomyosis was increased when compared with those of healthy individuals before interventional therapy (P < 0.05). Levels of hemoglobin in adenomyosispatients after surgery was increased compared with those before surgery (P < 0.05). The blood volume of menstruation, pain intensity, and volume of uterus in adenomyosispatients after surgery was significantly decreased when compared with those before surgery (P < 0.01). The survival rate of adenomyosispatients with high VEGF and CA125 levels was decreased. Serum levels of VEGF and CA125 had a high sensitivity and specificity for the prognosis of adenomyosis. CONCLUSIONS: The serum expression levels of VEGF and CA125 are related to the development of adenomyosis. VEGF and CA125 serum levels can be used for predicting the prognosis of adenomyosis.
Entities:
Keywords:
Adenomyosis; interventional therapy; vascular endothelial growth factor and cancer antigen 125
Authors: S Toyabe; S Seki; T Iiai; K Takeda; K Shirai; H Watanabe; H Hiraide; M Uchiyama; T Abo Journal: J Immunol Date: 1997-08-01 Impact factor: 5.422
Authors: V Karavasilis; V Malamou-Mitsi; E Briasoulis; E Tsanou; E Kitsou; N Pavlidis Journal: Int J Gynecol Cancer Date: 2006 Jan-Feb Impact factor: 3.437
Authors: Rainer Beckmann; Astrid Houben; Mersedeh Tohidnezhad; Nisreen Kweider; Athanassios Fragoulis; Christoph J Wruck; Lars O Brandenburg; Benita Hermanns-Sachweh; Mary B Goldring; Thomas Pufe; Holger Jahr Journal: Int J Mol Sci Date: 2014-09-01 Impact factor: 5.923